| DrugRepV_0585 | Clomiphene Citrate | Genito Urinary System and Sex Hormones | Female infertility | Ebola virus | EBOV/Kik | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 23785035 |
| DrugRepV_0586 | Clomiphene Citrate | Genito Urinary System and Sex Hormones | Female infertility | Ebola virus | EBOV/May | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 23785035 |
| DrugRepV_0587 | Clomiphene Citrate | Genito Urinary System and Sex Hormones | Female infertility | Ebola virus | SUDV | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 23785035 |
| DrugRepV_0588 | Clomiphene Citrate | Genito Urinary System and Sex Hormones | Female infertility | Ebola virus | MARV | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 23785035 |
| DrugRepV_0589 | Clomiphene Citrate | Genito Urinary System and Sex Hormones | Female infertility | Ebola virus | RAVV | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 23785035 |
| DrugRepV_0590 | Toremifene Citrate | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | EBOV/Kik | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 23785035 |
| DrugRepV_0591 | Toremifene Citrate | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | EBOV/May | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 23785035 |
| DrugRepV_0592 | Toremifene Citrate | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | SUDV | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 23785035 |
| DrugRepV_0593 | Toremifene Citrate | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | MARV | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 23785035 |
| DrugRepV_0594 | Toremifene Citrate | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | RAVV | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 23785035 |
| DrugRepV_1880 | PHA-690509 | NA | Cancer | Zika virus | PRVABC-59 (2015 Puerto Rican strain) | NA | Enzyme-linked immunosorbent assay | Decrease | NA | 27571349 |
| DrugRepV_1881 | Niclosamide | Antiparasitic products, Insectisides and Repellents | Tapeworm and intestinal fluke infections | Helminthiasis | Zika virus | PRVABC-59 (2015 Puerto Rican strain) | NA | Enzyme-linked immunosorbent assay | Decrease | Approved | 27571349 |
| DrugRepV_1967 | Emetine Dihydrochloride Hydrate | Antiparasitic products, Insectisides and Repellents | Protozoal disease | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | NA | 24841273 |
| DrugRepV_1968 | Chloroquine Diphosphate | Antiparasitic products, Insectisides and Repellents | Parasitic infections | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_1969 | Hydroxychloroquine Sulfate | Antiparasitic products, Insectisides and Repellents | Malaria | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_1970 | Mefloquine | Antiparasitic products, Insectisides and Repellents | Malaria | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24841273 |
| DrugRepV_1971 | Amodiaquine Dihydrochloride Dihydrate | Antiparasitic products, Insectisides and Repellents | Malaria | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24841273 |
| DrugRepV_1972 | Gemcitabine Hydrochloride | Antineoplastic and Immunomodulating Agents | Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_1973 | Tamoxifen Citrate | Antineoplastic and Immunomodulating Agents | Breast cancer | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_1974 | Toremifene Citrate | Antineoplastic and Immunomodulating Agents | Breast Cancer | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24841273 |
| DrugRepV_1975 | Terconazole | Genito Urinary System and Sex Hormones | Candidiasis (a yeast-like fungal infection) of the vulva and vagina | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_1976 | Anisomycin | Antibacterial | Bacterial infections | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Experimental | 24841273 |
| DrugRepV_1977 | Cycloheximide | Antibacterial | Bacterial and fungal infections | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | NA | 24841273 |
| DrugRepV_1978 | Homoharringtonine | Antineoplastic and Immunomodulating Agents | Chronic myeloid leukemia (CML) | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24841273 |
| DrugRepV_1979 | Benztropine Mesylate | Nervous System | Parkinson disease | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_1980 | Fluspirilene | Nervous System | Schizophrenia | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24841273 |
| DrugRepV_1981 | Thiothixene | Nervous System | Schizophrenia | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_1982 | Fluphenazine Hydrochloride | Nervous System | Psychosis | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_1983 | Promethazine Hydrochloride | Respiratory System | Allergic disorders | Nausea/vomiting | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24841273 |
| DrugRepV_1984 | Astemizole | Respiratory System | Allergies | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Withdrawn | 24841273 |
| DrugRepV_1985 | Chlorphenoxamine Hydrochloride | Respiratory System | Parkinson's | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Withdrawn | 24841273 |
| DrugRepV_1986 | Chlorpromazine Hydrochloride | Nervous System | Psychosis | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_1987 | Thiethylperazine Maleate | Respiratory System | Nausea | Vomiting | Mildly emetic cancer chemotherapy agents | Radiation therapy | Toxins | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Withdrawn | 24841273 |
| DrugRepV_1988 | Triflupromazine Hydrochloride | Nervous System | Psychosis | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_1989 | Clomipramine Hydrochloride | Nervous System | Psychosis | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_1990 | Imatinib Mesylate | Antineoplastic and Immunomodulating Agents | Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_1991 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24841273 |
| DrugRepV_2959 | Doxycycline | Antiinfectives For Systemic Use | Bacterial infections | Chikungunya virus | Clinical isolate of CHIKV (East/Central/South African genotype) | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 25970853 |
| DrugRepV_2960 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Chikungunya virus | Clinical isolate of CHIKV (East/Central/South African genotype) | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 25970853 |
| DrugRepV_2961 | Doxycycline-Ribavirin | NA | NA | Chikungunya virus | Clinical isolate of CHIKV (East/Central/South African genotype) | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 25970853 |
| DrugRepV_2962 | Doxycycline | Antiinfectives For Systemic Use | Bacterial infections | Chikungunya virus | Clinical isolate of CHIKV (East/Central/South African genotype) | NA | Enzyme-linked immunosorbent assay | Decrease (51 %) | Approved | 25970853 |
| DrugRepV_2963 | Ribavirin | Antiinfectives For Systemic Use | Hepatitis C virus | Chikungunya virus | Clinical isolate of CHIKV (East/Central/South African genotype) | NA | Enzyme-linked immunosorbent assay | Decrease (68 %) | Approved | 25970853 |
| DrugRepV_2964 | Doxycycline-Ribavirin | NA | NA | Chikungunya virus | Clinical isolate of CHIKV (East/Central/South African genotype) | NA | Enzyme-linked immunosorbent assay | Decrease (95 %) | Approved | 25970853 |
| DrugRepV_5628 | Minocycline | Antiinfectives For Systemic Use | Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae | Dengue virus | 16681 |  | Enzyme-linked immunosorbent assay | Decrease (20 %) | Approved, Investigational | 27396621 |
| DrugRepV_5629 | Minocycline | Antiinfectives For Systemic Use | Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae | Dengue virus | Hawaii | | Enzyme-linked immunosorbent assay | Decrease (20 %) | Approved, Investigational | 27396621 |
| DrugRepV_5630 | Minocycline | Antiinfectives For Systemic Use | Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae | Dengue virus | H87 | | Enzyme-linked immunosorbent assay | Decrease (30 %) | Approved, Investigational | 27396621 |
| DrugRepV_5631 | Minocycline | Antiinfectives For Systemic Use | Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae | Dengue virus | H241 | | Enzyme-linked immunosorbent assay | Decrease (30 %) | Approved, Investigational | 27396621 |
| DrugRepV_5634 | Lomefloxacin | Antiinfectives For Systemic Use | Bacterial infections (respiratory tract (chronic bronchitis) and urinary tract) | Dengue virus | 16681 | | Enzyme-linked immunosorbent assay | No significant effect (5 %) | Approved, Investigational | 27396621 |
| DrugRepV_5635 | Netilmicin | Antiinfectives For Systemic Use | Bacteremia | Septicaemia | Respiratory tract infections | Skin and soft-tissue infection | Burns | Wounds | Peri-operative infections caused by susceptible strains | Dengue virus | 16681 | | Enzyme-linked immunosorbent assay | No significant effect (0 %) | Approved, Investigational | 27396621 |
| DrugRepV_5968 | NITD008 | Antiviral | NA | Dengue virus | TS01 | | Enzyme-linked immunosorbent assay | Decrease (6 Fold) | NA | 19918064 |
| DrugRepV_6501 | Minocycline | Antiinfectives For Systemic Use | Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae | Human immunodeficiency virus | HIV-1ADA | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 15385252 |
| DrugRepV_6502 | Minocycline | Antiinfectives For Systemic Use | Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae | Human immunodeficiency virus | HIV-1ADA | | Enzyme-linked immunosorbent assay | Decrease (71-96 %) | Approved, Investigational | 15385252 |
| DrugRepV_6503 | Minocycline | Antiinfectives For Systemic Use | Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae | Human immunodeficiency virus | HIV-1ADA | | Enzyme-linked immunosorbent assay | Decrease (85 %) | Approved, Investigational | 15385252 |
| DrugRepV_6504 | Minocycline | Antiinfectives For Systemic Use | Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae | Human immunodeficiency virus | HIV-1BaL | | Enzyme-linked immunosorbent assay | Decrease (65 %) | Approved, Investigational | 15385252 |
| DrugRepV_6505 | Minocycline | Antiinfectives For Systemic Use | Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae | Human immunodeficiency virus | HIV-189.6 | | Enzyme-linked immunosorbent assay | Decrease (NA %) | Approved, Investigational | 15385252 |
| DrugRepV_6538 | Ruxolitinib | Antineoplastic and Immunomodulating Agents | Bone marrow cancer | Myelofibrosis | Human immunodeficiency virus | HIV-1LAI | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24419350 |
| DrugRepV_6539 | Tofacitinib | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Human immunodeficiency virus | HIV-1LAI | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24419350 |
| DrugRepV_6540 | Ruxolitinib | Antineoplastic and Immunomodulating Agents | Bone marrow cancer | Myelofibrosis | Human immunodeficiency virus | HIV-1LAI | | Enzyme-linked immunosorbent assay | Decrease (90 %) | Approved | 24419350 |
| DrugRepV_6541 | Tofacitinib | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Human immunodeficiency virus | HIV-1LAI | | Enzyme-linked immunosorbent assay | Decrease (90 %) | Approved, Investigational | 24419350 |
| DrugRepV_6542 | Ruxolitinib | Antineoplastic and Immunomodulating Agents | Bone marrow cancer | Myelofibrosis | Human immunodeficiency virus | HIV-2pROD10 | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24419350 |
| DrugRepV_6543 | Tofacitinib | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Human immunodeficiency virus | HIV-2pROD10 | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24419350 |
| DrugRepV_6544 | Ruxolitinib | Antineoplastic and Immunomodulating Agents | Bone marrow cancer | Myelofibrosis | Human immunodeficiency virus | HIV-2pROD10 | | Enzyme-linked immunosorbent assay | Decrease (90 %) | Approved | 24419350 |
| DrugRepV_6545 | Tofacitinib | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Human immunodeficiency virus | HIV-2pROD10 | | Enzyme-linked immunosorbent assay | Decrease (90 %) | Approved, Investigational | 24419350 |
| DrugRepV_6546 | Ruxolitinib | Antineoplastic and Immunomodulating Agents | Bone marrow cancer | Myelofibrosis | Human immunodeficiency virus | HIV-1LAI | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24419350 |
| DrugRepV_6547 | Tofacitinib | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Human immunodeficiency virus | HIV-1LAI | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24419350 |
| DrugRepV_6548 | Ruxolitinib | Antineoplastic and Immunomodulating Agents | Bone marrow cancer | Myelofibrosis | Human immunodeficiency virus | HIV-1LAI | | Enzyme-linked immunosorbent assay | Decrease (90 %) | Approved | 24419350 |
| DrugRepV_6549 | Tofacitinib | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Human immunodeficiency virus | HIV-1LAI | | Enzyme-linked immunosorbent assay | Decrease (90 %) | Approved, Investigational | 24419350 |
| DrugRepV_6550 | Ruxolitinib | Antineoplastic and Immunomodulating Agents | Bone marrow cancer | Myelofibrosis | Human immunodeficiency virus | PHA+IL2 | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24419350 |
| DrugRepV_6551 | Tofacitinib | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Human immunodeficiency virus | PHA+IL2 | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24419350 |
| DrugRepV_6552 | Ruxolitinib | Antineoplastic and Immunomodulating Agents | Bone marrow cancer | Myelofibrosis | Human immunodeficiency virus | PHA | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24419350 |
| DrugRepV_6553 | Tofacitinib | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Human immunodeficiency virus | PHA | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24419350 |
| DrugRepV_6554 | Ruxolitinib | Antineoplastic and Immunomodulating Agents | Bone marrow cancer | Myelofibrosis | Human immunodeficiency virus | NA | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24419350 |
| DrugRepV_6555 | Tofacitinib | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Human immunodeficiency virus | NA | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24419350 |
| DrugRepV_6556 | Tofacitinib | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Human immunodeficiency virus | xxLAI | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24419350 |
| DrugRepV_6557 | Tofacitinib | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Human immunodeficiency virus | M184V | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24419350 |
| DrugRepV_6558 | Tofacitinib | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Human immunodeficiency virus | K65R | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24419350 |
| DrugRepV_6559 | Tofacitinib | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Human immunodeficiency virus | L74V | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24419350 |
| DrugRepV_6560 | Tofacitinib | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Human immunodeficiency virus | A62V/V75I/F77L/F116Y/Q151M | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24419350 |
| DrugRepV_6561 | Tofacitinib | Antineoplastic and Immunomodulating Agents | Rheumatoid arthritis | Human immunodeficiency virus | 4XAZT(D67N/K70R/T215Y/K219Q) | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24419350 |
| DrugRepV_6562 | Ruxolitinib | Antineoplastic and Immunomodulating Agents | Bone marrow cancer | Myelofibrosis | Human immunodeficiency virus | xxLAI | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24419350 |
| DrugRepV_6563 | Ruxolitinib | Antineoplastic and Immunomodulating Agents | Bone marrow cancer | Myelofibrosis | Human immunodeficiency virus | M184V | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24419350 |
| DrugRepV_6564 | Ruxolitinib | Antineoplastic and Immunomodulating Agents | Bone marrow cancer | Myelofibrosis | Human immunodeficiency virus | K65R | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24419350 |
| DrugRepV_6565 | Ruxolitinib | Antineoplastic and Immunomodulating Agents | Bone marrow cancer | Myelofibrosis | Human immunodeficiency virus | L74V | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24419350 |
| DrugRepV_6566 | Ruxolitinib | Antineoplastic and Immunomodulating Agents | Bone marrow cancer | Myelofibrosis | Human immunodeficiency virus | A62V/V75I/F77L/F116Y/Q151M | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24419350 |
| DrugRepV_6567 | Ruxolitinib | Antineoplastic and Immunomodulating Agents | Bone marrow cancer | Myelofibrosis | Human immunodeficiency virus | 4XAZT(D67N/K70R/T215Y/K219Q) | | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved | 24419350 |